Goserelin
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | ZOLADEX | — | 1993-02-02 – 1998-07-27 | fda.gov ↗ |
| Approved | US (FDA) | ZOLADEX | — | 1989-12-29 | fda.gov ↗ |
Trials 156 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07516704 | Apr 2026 → Dec 2027 expected | prostate cancer | Zhongda Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT03511196 | Sep 2018 → Jun 2022 overdue | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04060043 | Feb → Dec 2017 | prostate cancer | CMX Research | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT07310420 | Jun → Nov 2026 expected | breast cancer | TerSera Therapeutics LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT04428684 | Oct 2018 → Apr 2020 | uterine disorder | Peptigroupe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02023463 | Apr 2014 → Jul 2017 overdue | prostate adenocarcinoma | Thomas Jefferson University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02911350 | May 2000 → Dec 2016 | prostate cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00669162 | Aug 2012 → Aug 2016 | prostate cancer | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00653757 | Mar 2002 → Dec 2006 | prostate cancer | Mayo Clinic | Completed | No outcome recorded |
| Phase 267 trials | ||||||
| Phase 2 | NCT07610733 | Jun 2026 → Sep 2027 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07460752 | May 2026 → Sep 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT07287098 | May 2026 → Jan 2029 expected | breast neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07450599 | Apr 2026 → Jun 2028 expected | — | Bayer | Recruiting | No outcome recorded |
| Phase 2 | NCT07158021 | Jan 2026 → Jan 2028 expected | female breast carcinoma, invasive breast carcinoma | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07313241 | Nov 2025 → Nov 2030 expected | prostate cancer | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06953882 | Jul 2025 → Sep 2030 expected | Her2-receptor negative breast cancer | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT06772441 | Nov 2024 → Oct 2026 expected | prostate cancer | German Oncology Center, Cyprus | Recruiting | No outcome recorded |
| Phase 2 | NCT06225284 | Aug 2024 → Dec 2026 expected | triple-negative breast carcinoma | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06385847 | May 2024 → May 2025 | prostate cancer | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 2 | NCT06387056 | Apr 2024 → Apr 2026 overdue | metastatic prostate carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05607004 | Feb 2023 → Nov 2026 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive breast carcinoma | Atossa Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05694819 | Apr 2020 → Aug 2024 | salivary gland cancer | National Cancer Center Hospital East | Completed | No outcome recorded |
| Phase 2 | NCT03942653 | May 2019 → Jul 2026 overdue | salivary gland carcinoma | Manish Patel | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03860987 | Apr 2019 → May 2026 | prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04536467 | Mar 2019 → Dec 2020 | primary ovarian failure | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2 | NCT03839823 | Feb 2019 → Apr 2022 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03628066 | Oct 2018 → Nov 2020 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 2 | NCT03361735 | Aug 2018 → Mar 2024 overdue | prostate adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03444025 | Mar 2018 → Mar 2021 | triple-negative breast carcinoma | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03475758 | Mar 2018 → Mar 2020 | primary ovarian failure | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02972060 | Dec 2017 → Jan 2023 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03279250 | Oct 2017 → May 2021 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03272477 | Oct 2017 → Jul 2020 | breast cancer | Palleos Healthcare GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02476786 | Jan 2017 → Jan 2027 expected | breast cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT02624973 | Apr 2016 → Jun 2020 overdue | breast cancer | Haukeland University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02544191 | Dec 2015 → Dec 2017 | azoospermia | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT02430480 | Jun 2015 → Dec 2019 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02603679 | Feb 2015 → Jul 2021 overdue | estrogen-receptor positive breast cancer | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01989780 | Jan 2014 → Jun 2018 | breast cancer | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT01776008 | Jan 2013 → May 2015 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01368263 | Sep 2011 → May 2013 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT01377389 | Jun 2011 → Apr 2017 | prostate cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01023061 | Mar 2010 → Sep 2015 | prostate adenocarcinoma | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00970203 | Sep 2009 → Oct 2018 | prostate cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00937768 | Jul 2009 → Jun 2012 | prostate adenocarcinoma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT00771017 | Jul 2008 → ? | prostate cancer | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 2 | NCT00658697 | Jun 2008 → Sep 2014 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00528866 | Apr 2008 → Dec 2013 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00589472 | Nov 2007 → Jun 2010 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00432172 | Apr 2007 → Sep 2010 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT00498901 | Feb → Dec 2007 | breast cancer | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT00544830 | Jul 2006 → Mar 2011 overdue | prostate adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00382057 | May 2006 → Mar 2011 | metabolic syndrome X | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00322348 | Apr 2006 → Nov 2009 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00349557 | Apr 2006 → ? | prostate cancer | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00348998 | Apr 2006 → ? | prostate cancer | Virginia Mason Hospital/Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00303524 | Feb 2006 → Aug 2007 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00532272 | Oct 2005 → Apr 2008 | breast cancer | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT00217659 | Sep 2005 → Jan 2007 | breast cancer | SWOG Cancer Research Network | Withdrawn | No outcome recorded |
| Phase 2 | NCT01076335 | May 2005 → Jun 2015 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00196846 | Mar 2005 → Dec 2008 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00103376 | Oct 2004 → Oct 2009 | prostate cancer | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 2 | NCT00165399 | Mar 2004 → Dec 2005 | prostate adenocarcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01014507 | Jan 2004 → Sep 2009 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT00028769 | Dec 2001 → Jun 2010 | prostate cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00235937 | Dec 2001 → Dec 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00586898 | Jul 2001 → Mar 2009 | cancer, prostate disorder | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00016913 | May 2001 → Jul 2007 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT01250717 | Jan 2001 → May 2011 | prostate cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00186121 | Oct 2000 → May 2013 | breast cancer | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00012090 | Sep 2000 → Apr 2004 | fallopian tube carcinoma, ovarian carcinoma, peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00006359 | Sep 2000 → Oct 2007 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00010010 | Jun 2000 → May 2001 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06009627 | Apr 2023 → Mar 2025 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05253066 | Feb → Jul 2022 | breast neoplasm | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03373708 | Dec 2017 → Dec 2019 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2/3 | NCT02221999 | Sep 2013 → Jan 2019 overdue | breast mucinous carcinoma, inflammatory breast carcinoma, invasive tubular breast carcinoma | RenJi Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01603420 | Jul 2012 → May 2014 | prostate cancer | Proton Collaborative Group | Terminated | No outcome recorded |
| Phase 347 trials | ||||||
| Phase 3 | NCT03936933 | Oct 2020 → Sep 2024 | breast cancer | Eurofarma Laboratorios S.A. | Terminated | No outcome recorded |
| Phase 3 | NCT03936218 | Sep 2020 → Nov 2023 | prostate cancer | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT03658213 | Mar 2020 → Nov 2021 | breast cancer | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT03054168 | Dec 2016 → Nov 2018 | muscular atrophy | University of Nottingham | Unknown | No outcome recorded |
| Phase 3 | NCT02532400 | Mar 2016 → Mar 2019 | breast cancer | Ruijin Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02518191 | Sep 2015 → Jan 2021 | female breast carcinoma | Xiangyun Zong | Completed | No outcome recorded |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02535221 | Jul 2015 → Jun 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
| Phase 3 | NCT02483767 | Jun 2015 → Nov 2016 | breast cancer | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02132390 | May 2014 → May 2024 | breast cancer, chemotherapy-induced toxicity | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02003209 | Feb 2014 → Oct 2016 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01638247 | Aug 2012 → May 2018 | male breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01622361 | Jun 2012 → Feb 2016 | breast cancer | Asan Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01492972 | Jan 2012 → Dec 2027 expected | prostate cancer | Proton Collaborative Group | Recruiting | No outcome recorded |
| Phase 3 | NCT01368588 | Jul 2011 → Apr 2025 overdue | prostate cancer | Radiation Therapy Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01530607 | Nov 2009 → Nov 2012 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 3 | NCT00936390 | Sep 2009 → Oct 2020 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01712893 | Jun 2009 → Aug 2017 | breast cancer | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT00912548 | May 2009 → Dec 2015 | breast cancer | Korean Breast Cancer Study Group | Unknown | No outcome recorded |
| Phase 3 | NCT00948805 | Jan → Dec 2009 | infertility disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT01352091 | May 2008 → May 2015 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00567580 | Feb 2008 → Jul 2018 | prostate cancer | Radiation Therapy Oncology Group | Unknown | No outcome recorded |
| Phase 3 | NCT01581944 | Jan 2008 → Dec 2011 | leiomyoma | Mt. Hope Maternity Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00541047 | Nov 2007 → Jul 2022 | prostate cancer, sexual disorder | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT00430183 | May 2007 → Oct 2018 overdue | prostate cancer | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00439751 | Apr 2007 → Dec 2015 | prostate cancer | Ontario Clinical Oncology Group (OCOG) | Completed | No outcome recorded |
| Phase 3 | NCT00423475 | Oct 2006 → Mar 2015 | prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00429403 | Aug 2006 → Jul 2010 | breast cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT00427245 | Aug 2004 → ? | breast cancer, infertility disorder, premature menopause | Anglo Celtic Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00068601 | Oct 2003 → Jan 2014 | breast cancer, infertility disorder, premature menopause | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00067015 | May 2003 → Oct 2004 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00021450 | Apr 2001 → Apr 2008 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00014586 | Jan 2001 → Feb 2003 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 3 | NCT00223145 | Dec 2000 → Dec 2026 expected | prostate cancer | Abdenour Nabid | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00223171 | Oct 2000 → Dec 2026 expected | prostate cancer | University of Sherbrooke | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00005044 | Feb 2000 → Sep 2012 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002881 | Oct 1996 → Apr 1998 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002651 | May 1995 → Jun 2013 | prostate cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00769548 | Apr 1995 → Apr 2001 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002597 | Oct 1994 → Jul 2011 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002580 | Jun 1993 → ? | breast cancer | Scottish Cancer Therapy Network | Completed | No outcome recorded |
| Phase 3 | NCT00002582 | Jun 1993 → Apr 2007 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 3 | NCT00309478 | Dec 1990 → Jun 2004 | female breast carcinoma | Austrian Breast & Colorectal Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00002460 | Sep 1987 → ? | female breast carcinoma | Cancer Research UK | Unknown | No outcome recorded |
| Phase 3 | NCT00849082 | May 1987 → Nov 1995 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00767286 | ? → Nov 2003 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00888082 | ? → Apr 2012 | breast cancer, ovarian dysfunction | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT06523530 | Nov 2024 → Apr 2027 expected | NAFLD1, endometriosis | Aristotle University Of Thessaloniki | Recruiting | No outcome recorded |
| Phase 4 | NCT06455969 | Jul 2024 → Aug 2026 overdue | hypogonadism, musculoskeletal system disorder | Bradley Nindl | Recruiting | No outcome recorded |
| Phase 4 | NCT05333328 | Feb 2023 → Jan 2031 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Gangnam Severance Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03971110 | Jan 2021 → Nov 2022 | prostate cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 4 | NCT04248621 | Jan 2020 → Apr 2022 | prostate neoplasm | Wonju Severance Christian Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01738724 | Jan 2012 → Dec 2016 | leiomyoma | University of Sao Paulo | Terminated | No outcome recorded |
| Phase 4 | NCT00851461 | Apr 2008 → Nov 2011 | Kennedy disease, bulbospinal muscular atrophy | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00654524 | Mar 2008 → Dec 2009 | endometriosis | Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT00286351 | Jan 2005 → ? | endometriosis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00293696 | Oct 2004 → Nov 2006 | prostate cancer | Tampere University | Completed | No outcome recorded |
| Phase 4 | NCT00255268 | Aug 2004 → ? | metastatic prostate carcinoma | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 4 | NCT00293670 | May 1997 → Apr 2015 | — | Tampere University | Unknown | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07552493 | May 2026 → May 2027 expected | disease related to hematopoietic stem cell transplant, ovarian dysfunction | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07552506 | May 2026 → May 2027 expected | aplastic anemia, disease related to hematopoietic stem cell transplant, ovarian dysfunction | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07552480 | May 2026 → May 2027 expected | disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid system neoplasm, ovarian dysfunction | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07172685 | Jul 2025 → Jun 2026 overdue | prostate cancer | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| — | NCT06636591 | Dec 2024 → Jan 2026 | Her2-receptor negative breast cancer, female breast carcinoma | Fudan University | Completed | No outcome recorded |
| — | NCT05898321 | Jun 2023 → Dec 2024 | submucous uterine fibroid | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| — | NCT04220398 | Jan 2020 → Dec 2022 | chemotherapy-induced toxicity, prostate carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03440879 | Sep 2018 → Mar 2023 | prostate cancer | Norwegian School of Sport Sciences | Terminated | No outcome recorded |
| — | NCT02932761 | Nov 2016 → Jan 2018 | — | Xipeng Wang | Unknown | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT02779387 | May 2016 → May 2020 | infertility disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT00827307 | Jun 2008 → Jun 2011 | hyperlipidemia | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| — | NCT00488722 | Apr 2007 → Mar 2009 | breast cancer | Tianjin Medical University | Unknown | No outcome recorded |
| — | NCT00114114 | Sep 2004 → Nov 2017 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00031850 | Mar 2000 → May 2007 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
Also used as a comparator or background therapy in 192 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07389187 Background | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 120 trials | ||||||
| Phase 1 | NCT05617885 Background | Aug 2023 → Jul 2025 | metastatic prostate carcinoma | Praful Ravi, MB BCHir, MRCP | Completed | No outcome recorded |
| Phase 1 | NCT05856630 Comparator | May → Dec 2023 | prostate cancer | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05755581 Comparator | Apr 2023 → Apr 2025 | breast cancer | Sohag University | Unknown | No outcome recorded |
| Phase 1 | NCT05140512 Comparator | Feb → Sep 2021 | prostate cancer | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03450109 Comparator | Dec 2017 → Oct 2018 | prostate cancer | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03332797 Background | Nov 2017 → Jul 2027 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02586675 Background | Feb 2016 → May 2017 | female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT02626507 Background | Jan 2016 → Feb 2022 | breast cancer | Hoffman Oncology | Unknown | No outcome recorded |
| Phase 1 | NCT02472275 Background | Jun 2015 → Aug 2019 | prostate adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02333370 Background | Feb 2015 → Sep 2022 | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01149356 Background | Oct 2010 → Dec 2012 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, male breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT02592031 Comparator | Feb → May 2009 | — | Merckle GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00631527 Background | Feb 2008 → Jan 2015 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00512668 Background | Sep 2007 → Jan 2008 | prostate adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00099086 Background | Jan 2007 → Jan 2011 | prostate cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT00438321 Comparator | Sep 2006 → Feb 2010 | metabolic syndrome X | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT00482807 Background | Aug 2004 → Mar 2010 | prostate cancer | University of Nebraska | Completed | No outcome recorded |
| Phase 1 | NCT00328614 Background | Mar 2003 → Feb 2009 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT00026377 Background | Nov 2001 → Mar 2002 | prostate cancer | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT01240928 Background | — | breast cancer | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07596212 Background | Jul 2026 → Jul 2028 expected | hormone receptor-positive breast cancer, hypoactive sexual desire disorder | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05003752 Background | Aug 2021 → Dec 2022 overdue | prostate adenocarcinoma, radiation-induced disorder | German Oncology Center, Cyprus | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03587285 Background | Sep 2018 → Jul 2021 | prostate neoplasm | Guangzhou University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT01163084 Background | Jul 2010 → Jun 2012 | prostate adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00003394 Background | Apr 1998 → Apr 2003 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 287 trials | ||||||
| Phase 2 | NCT07142551 Background | Mar 2026 → Jun 2030 expected | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT07268794 Background | Nov 2025 → Apr 2027 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06922318 Background | Aug 2025 → Aug 2031 expected | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT06832774 Background | Aug 2025 → Dec 2027 expected | metastatic prostate carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06528210 Background | Apr 2025 → Jun 2026 | prostate adenocarcinoma | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT06348134 Background | Mar 2025 → Jul 2034 expected | HER2 positive breast carcinoma, Her2-receptor negative breast cancer, female breast carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT07553988 Background | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06582446 Background | Sep 2024 → Aug 2026 overdue | prostate cancer | German Oncology Center, Cyprus | Recruiting | No outcome recorded |
| Phase 2 | NCT06656624 Background | Aug 2024 → Dec 2025 overdue | female breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06378866 Comparator | Jun 2024 → Feb 2031 expected | castration-resistant prostate carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06575257 Background | May 2024 → May 2026 overdue | prostate cancer | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06059118 Background | Oct 2023 → Jan 2027 expected | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT05949541 Background | Jul 2023 → Jul 2026 overdue | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05983107 Background | Jul 2023 → Jul 2026 overdue | hormone receptor-positive breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05498272 Background | Feb 2023 → Aug 2026 overdue | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, prostate adenocarcinoma | Rana McKay, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05720260 Background | Jan 2023 → Dec 2024 overdue | estrogen-receptor positive breast cancer | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05594095 Background | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05163106 Background | Dec 2022 → Jul 2024 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, luminal A breast carcinoma +1 | University Hospital, Akershus | Completed | No outcome recorded |
| Phase 2 | NCT05513365 Background | Sep 2022 → Sep 2025 overdue | salivary duct carcinoma | Radboud University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05212857 Background | Apr 2022 → Feb 2024 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04862143 Background | Mar → Sep 2022 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05085002 Background | Dec 2021 → Nov 2023 | female breast carcinoma | EQRx, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04931342 Background | Oct 2021 → Feb 2028 expected | ovarian cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04734730 Background | May 2021 → Aug 2027 expected | prostate adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04736108 Background | May 2021 → Oct 2022 | prostate cancer | West China Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04551495 Background | Jan 2021 → Jan 2025 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive lobular breast carcinoma | Jules Bordet Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04992026 Background | Jan 2021 → Dec 2024 | metastatic prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 2 | NCT04293393 Background | Oct 2020 → Jun 2023 overdue | female breast carcinoma | Spanish Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04465097 Background | Jul 2020 → Oct 2023 | breast cancer | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 2 | NCT05004142 Background | Jun 2020 → Dec 2021 | breast cancer | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04126070 Background | May 2020 → Jul 2025 overdue | metastatic prostate carcinoma, prostate adenocarcinoma | Xiao X. Wei, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04325828 Background | Apr 2020 → Jun 2021 overdue | tumor of salivary gland | Janssen Pharmaceutical K.K. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05406999 Background | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT03822468 Background | Jun 2019 → Jun 2021 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02917005 Background | May 2019 → Dec 2021 | breast cancer | Hamdy A. Azim | Unknown | No outcome recorded |
| Phase 2 | NCT03809000 Background | Apr 2019 → Apr 2023 overdue | prostate cancer | RTOG Foundation, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03899077 Comparator | Apr 2019 → Aug 2025 | prostate cancer | Cancer Research Antwerp | Unknown | No outcome recorded |
| Phase 2 | NCT04356430 Background | Apr 2019 → Mar 2021 | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 2 | NCT02789878 Background | Jan 2019 → Apr 2022 | prostate cancer | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT03944434 Background | Dec 2018 → Dec 2024 overdue | breast cancer | Fondazione Sandro Pitigliani | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03573648 Comparator | Nov 2018 → Sep 2026 expected | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03671330 Background | Aug 2018 → Apr 2022 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03696186 Background | Aug 2018 → Aug 2022 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03311555 Background | Mar 2018 → Dec 2022 | prostate cancer | Andrew J. Armstrong, MD | Completed | No outcome recorded |
| Phase 2 | NCT02867020 Comparator | Oct 2017 → Oct 2019 | prostate cancer | Latin American Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT03056755 Background | Aug 2017 → Jun 2021 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02907918 Background | Jun 2017 → Aug 2020 | breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT03007979 Background | Jun 2017 → Mar 2020 | breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02582749 Background | Apr 2016 → Sep 2017 | metastatic carcinoma in the bone, prostate cancer | Ajjai Alva, MD | Terminated | No outcome recorded |
| Phase 2 | NCT02678520 Background | Dec 2015 → Feb 2016 | prostate cancer | University of Kansas Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02278185 Comparator | Nov 2015 → Apr 2019 | prostate adenocarcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT02592083 Background | Oct 2015 → Feb 2019 overdue | hormone receptor-positive breast cancer | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02742675 Background | Sep 2015 → Mar 2021 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT02440230 Background | May 2015 → Dec 2021 | breast cancer | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02313051 Background | Dec 2014 → Dec 2016 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02217566 Background | Sep 2014 → Oct 2018 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02168062 Background | Jun 2014 → May 2018 | prostate adenocarcinoma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT02059213 Background | Jun 2014 → Sep 2017 | prostate cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02058706 Background | May 2014 → Mar 2021 | prostate adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01717053 Background | Jan 2014 → Aug 2017 | prostate cancer | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT02072512 Comparator | Jan 2014 → Nov 2015 | breast cancer | Hospital Affiliated to Military Medical Science, Beijing | Unknown | No outcome recorded |
| Phase 2 | NCT01723774 Background | Apr 2013 → Apr 2021 overdue | breast neoplasm | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01790126 Comparator | Mar 2013 → Mar 2019 | prostate cancer | Aragon Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01786265 Background | Feb 2013 → Feb 2027 expected | prostate adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01750398 Background | Jan 2013 → Jun 2015 | prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT01531205 Background | May 2012 → Sep 2013 | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02107391 Comparator | Mar 2012 → Dec 2015 | prostate cancer | SOTIO a.s. | Completed | No outcome recorded |
| Phase 2 | NCT01496131 Background | Oct 2011 → Nov 2016 | prostate cancer | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT01240941 Background | Feb 2011 → Jun 2012 | breast cancer | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT01266213 Background | Dec 2010 → Jun 2018 | estrogen-receptor positive breast cancer | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01120236 Background | Dec 2010 → Jun 2015 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01252693 Comparator | Nov 2010 → Sep 2014 | prostate cancer | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT01205685 Background | May 2010 → Jul 2011 | breast cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01088529 Background | Dec 2009 → Mar 2013 | prostate cancer | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01013506 Background | Aug → Dec 2009 | breast cancer | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00776594 Background | Oct 2008 → Dec 2014 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00769795 Background | Oct 2008 → Aug 2011 | prostate cancer | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00398489 Background | Oct 2006 → ? | breast cancer | Technical University of Munich | Unknown | No outcome recorded |
| Phase 2 | NCT00298155 Comparator | Jul 2006 → Jun 2010 | cancer, prostate neoplasm | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00454571 Background | Jun 2006 → Dec 2010 | prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00108732 Background | Feb 2006 → Oct 2010 | grade III prostatic intraepithelial neoplasia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00167648 Comparator | Mar 2005 → Dec 2006 | prostate cancer | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00081159 Background | Jul 2004 → Sep 2014 | metastatic malignant neoplasm, prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00170157 Background | Jun 2004 → Apr 2011 | prostate adenocarcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00500110 Background | Jun 2003 → Feb 2010 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00283803 Background | Mar 2002 → Oct 2011 | prostate cancer | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00002889 Background | May 1997 → Jan 2004 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06282588 Background | Dec 2023 → Jul 2030 expected | prostate cancer | Cancer Research Antwerp | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 expected | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03070886 Background | Apr 2017 → Oct 2025 | prostate adenocarcinoma | NRG Oncology | Completed | No outcome recorded |
| Phase 2/3 | NCT02685397 Background | Oct 2016 → Apr 2027 expected | castration-resistant prostate carcinoma | Sir Mortimer B. Davis - Jewish General Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01218581 Comparator | Dec 2005 → Jan 2010 | — | Mansoura University | Completed | No outcome recorded |
| Phase 356 trials | ||||||
| Phase 3 | NCT07477626 Background | Mar 2026 → Dec 2033 expected | metastatic malignant neoplasm in the lymph nodes, prostate cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05827081 Background | Feb 2024 → Sep 2029 expected | female breast carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06447623 Background | Feb 2024 → Feb 2027 expected | hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05879926 Comparator | Oct 2023 → Jan 2032 expected | breast cancer | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05891093 Background | Jun 2023 → May 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05781217 Comparator | Mar → Dec 2023 overdue | prostate cancer | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | Recruiting | No outcome recorded |
| Phase 3 | NCT05439499 Comparator | Mar 2022 → Sep 2024 | female breast carcinoma | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05438810 Background | Jan 2022 → Feb 2024 | female breast carcinoma | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05050084 Background | Dec 2021 → Nov 2026 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04455750 Background | Oct 2021 → Mar 2027 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04961996 Background | Aug 2021 → Aug 2025 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04484818 Background | Mar 2021 → Sep 2026 expected | prostate carcinoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04711252 Background | Jan 2021 → Aug 2026 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513717 Background | Jan 2021 → Dec 2033 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04557059 Background | Nov 2020 → Aug 2029 expected | prostate neoplasm | Janssen Pharmaceutica N.V., Belgium | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04478266 Background | Oct 2020 → Jun 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT04423211 Background | Oct 2020 → Dec 2032 expected | metastatic prostate carcinoma, prostate adenocarcinoma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04181203 Background | Jan 2020 → Sep 2028 expected | prostate cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04563936 Comparator | Jan 2020 → Mar 2021 | prostate cancer | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03969121 Comparator | Jul 2019 → Dec 2021 | female breast carcinoma, hormone receptor-positive breast cancer | Kyoto Breast Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT03678025 Background | Sep 2018 → Apr 2028 expected | prostate adenocarcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT03664895 Comparator | Sep 2018 → Dec 2024 | invasive breast carcinoma | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03423199 Background | Feb 2018 → Sep 2025 | breast cancer | National Cancer Center, Japan | Unknown | No outcome recorded |
| Phase 3 | NCT03447132 Comparator | Dec 2017 → Apr 2021 | breast cancer | International Cancer Research Group, United Arab Emirates | Completed | No outcome recorded |
| Phase 3 | NCT02941926 Background | Nov 2016 → Nov 2019 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03096847 Background | Oct 2016 → Dec 2018 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02914158 Background | Mar 2016 → Dec 2023 | breast cancer | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02278120 Background | Nov 2014 → Aug 2017 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02115282 Background | Mar 2014 → May 2020 overdue | Her2-receptor negative breast cancer, breast adenocarcinoma, female breast carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01674140 Background | Sep 2013 → Dec 2022 overdue | breast cancer | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01964170 Comparator | Aug 2013 → Jun 2015 | prostate cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01744366 Comparator | Jan 2013 → May 2015 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01546987 Background | May 2012 → Nov 2021 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01242748 Comparator | Oct 2010 → Dec 2011 | prostate cancer | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00884273 Comparator | Aug 2009 → Mar 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00946920 Comparator | Jun 2009 → Mar 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00833248 Comparator | Apr 2009 → Sep 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00831233 Comparator | Apr 2009 → Jun 2010 | prostate cancer | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00651326 Comparator | Jun 2008 → May 2010 | prostate cancer | NCIC Clinical Trials Group | Terminated | No outcome recorded |
| Phase 3 | NCT00664456 Comparator | Apr 2008 → Apr 2022 | prostate cancer | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | No outcome recorded |
| Phase 3 | NCT00605267 Background | Oct 2007 → Nov 2009 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00303784 Comparator | Mar 2006 → Aug 2021 | anemia, osteoporosis, prostate cancer | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT00288080 Background | Dec 2005 → Apr 2014 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00388804 Comparator | Feb 2005 → Apr 2011 | prostate cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT00104715 Background | Oct 2004 → Dec 2011 | prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00055731 Background | Nov 2002 → Dec 2010 | prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00053911 Background | Nov 2002 → Apr 2004 | breast cancer | UNICANCER | Terminated | No outcome recorded |
| Phase 3 | NCT00047099 Background | Aug 2001 → Feb 2012 | breast cancer | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT01394263 Comparator | May 2000 → Dec 2001 | prostate adenocarcinoma | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT00004635 Background | Mar 2000 → Jan 2005 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00004054 Background | Jan 2000 → Apr 2010 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00004124 Background | Oct 1999 → Aug 2017 | prostate cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00003653 Comparator | Jan 1999 → Oct 2010 | prostate cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00841113 Comparator | Jan 1999 → Feb 2001 | prostate cancer | Speciality European Pharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT00116220 Comparator | Sep 1995 → Apr 2001 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00002633 Comparator | Feb 1995 → Sep 2011 | prostate cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT05700903 Comparator | Sep 2023 → Jul 2025 | dysautonomia, hypertensive disorder, kidney disorder, prostate cancer | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT05161195 Background | Jul 2022 → Jun 2030 expected | metastatic malignant neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05013242 Comparator | Dec 2020 → Nov 2021 | endometriosis | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT03591549 Background | Aug 2018 → Aug 2021 | breast cancer | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT01673984 Comparator | Aug 2012 → Feb 2014 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 4 | NCT01682642 Comparator | Mar 2012 → Oct 2014 | endometriosis, infertility disorder | AZ Jan Palfijn Gent | Completed | No outcome recorded |
| Phase 4 | NCT00746031 Comparator | Dec 2008 → Sep 2010 | leiomyoma | University of Edinburgh | Completed | No outcome recorded |
| Phase 4 | NCT02749825 Comparator | Sep 2002 → May 2006 | prostate cancer | Pharmatech | Terminated | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07483658 Background | May 2026 → Dec 2029 expected | prostate cancer | CHU de Quebec-Universite Laval | Recruiting | No outcome recorded |
| — | NCT05628363 Background | Jan 2023 → Oct 2025 overdue | prostate cancer | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| — | NCT04894188 Background | Jan 2022 → Jul 2024 overdue | prostate cancer | National Taiwan University Hospital | Recruiting | No outcome recorded |
| — | NCT02594072 Background | Apr 2016 → Dec 2024 | prostate cancer | University of British Columbia | Unknown | No outcome recorded |
| — | NCT02454543 Background | May 2015 → Dec 2019 overdue | prostate cancer | Martini-Klinik am UKE GmbH | Active not recruiting | No outcome recorded |
| — | NCT02346253 Background | Jan 2015 → Dec 2021 | prostate adenocarcinoma | Stanford University | Completed | No outcome recorded |
| — | NCT02661789 Comparator | Jan 2011 → Dec 2012 | major depressive disorder, neurodegenerative disease, postpartum depression, postpartum psychosis +1 | Gitte Moos Knudsen | Completed | No outcome recorded |
| — | NCT00433173 Comparator | May 2006 → Feb 2011 | metabolic syndrome X | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Suspended | No outcome recorded |
| — | NCT00536653 Comparator | Oct 1999 → Jan 2007 | osteoporosis | Wirral University Teaching Hospital NHS Trust | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 349 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Goserelin | “All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing...” NCT01368588 ↗241“METHODS: Forty women were assessed for eligibility at gynaecology clinics in the region, of whom thirty premenopausal women scheduled for hysterectomy due to symptomatic...” PMID 24608161 ↗ Mar 2014 “Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single...” NCT03054168 ↗ “This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗ “Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the...” NCT04557059 ↗ “Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve...” NCT02867020 ↗ “In patients randomized to receive GnRHa, 3.6 mg of goserelin or 3.75 mg of leuprorelin was injected subcutaneously once every 28 days from 1 to 2 weeks before the first cycle...” PMID 34967844 ↗ Feb 2022 “A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy Using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients With...” NCT03971110 ↗ “LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3...” NCT01088529 ↗ “Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days...” NCT03969121 ↗ “Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or...” NCT02440230 ↗ “Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70...” NCT00223171 ↗ “The primary objective of the study is to demonstrate non-inferiority of a generic formulation of goserelin 3.6 mg as compared to Zoladex ® 3.6 mg on endometrial thinning prior...” NCT04428684 ↗ “The goserelin implant (Zoladex®) 3.6 mg is administered subcutaneously every 28 days into the anterior abdominal wall using a pre-filled syringe with a 16G needle (outer...” NCT06385847 ↗ “Phase II Clinical Study of Darsilide Combined With Exemestane+Goserelin Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients” NCT06009627 ↗ “Flutamide, FLUT, NSC-147834; Goserelin, Zoladex, ZDX, NSC-606864; with irradiation of the whole pelvis followed by a boost to the prostate using photons of at least 6 MV.” NCT00769548 ↗ “All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery.” NCT01531205 ↗ “1-month GnRH (goserelin 3.6 mg depot or goserelin 3.6 mg implant or leuprolide 3.75 mg depot) +endocrine therapy (aromatase inhibitor/tamoxifen±CDK4/6 inhibition)” NCT07610733 ↗ “Goserelin, a gonadotropin releasing hormone agonist (GnRHα) was used to suppress endogenous gonadotropin levels (gonadotropin reset) in the NOA patients” PMID 30243299 ↗ Sep 2018 “AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).” NCT00664456 ↗ “Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.” NCT01603420 ↗ “Androgen deprivation therapy includes available GnRH agonists and antagonists, such as Triptorelin, Leuprolide, Goserelin and Degarelix.” NCT07477626 ↗ “The specific dosage is goserelin 3.6 mg, administered as a subcutaneous injection into the anterior abdominal wall once every 28 day” NCT07516704 ↗ “Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.” NCT04992026 ↗ “LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration” NCT00528866 ↗ “Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w” NCT02532400 ↗ “Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)” NCT03573648 ↗ “gonadotropin-releasing hormone agonist ("Leuprorelin", "Goserelin" or "Triptorelin") 3.75mg/28d injection subcutaneously” NCT05945407 ↗ “luteinizing hormone-releasing hormone (LHRH) agonist (e.g., leuprolide acetate, goserelin, buserelin, or triptorelin)” NCT00288080 ↗ “ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.” NCT03511196 ↗ “Drugs, such as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.” NCT00103376 ↗ “Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)” NCT03696186 ↗ “gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician)” NCT03279250 ↗ “Maintenance of ADT using GnRH agonist or antagonist (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix).” NCT07389187 ↗ “Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months” NCT00004054 ↗ “LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix.” NCT00936390 ↗ “GnRH agonist or antagonist (leuprolide, goserelin, degarelix) administered as per institutional standard.” NCT07313241 ↗ “GnRH analog Goserelin acetate 3.6 mg every 4 weeks with tamoxifen 20 mg daily for premenopausal patients” NCT05755581 ↗ “If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.” NCT04465097 ↗ “Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months.” NCT05879926 ↗ “Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.” NCT05983107 ↗ “Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.” NCT01076335 ↗ “Hormonal therapy with a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin)” NCT07483658 ↗ “ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix).” NCT05628363 ↗ “GnRHa (Goserelin 10.8 mg sustained-release implant, subcutaneous injection, every 3 months)” NCT07172685 ↗ “GNRH agonist (leuprolide, goserelin, triptorelin) or GNRH antagonist (relugolix, degarelix)” NCT06528210 ↗ “Goserelin acetate implant for pre- or perimenopausal female and male participants only” NCT05085002 ↗ “Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable.” NCT04931342 ↗ “Some participants will also get either goserelin or leuprorelin once every month.” NCT04711252 ↗ “Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.” NCT03944434 ↗ “gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide)” NCT02454543 ↗ “A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.” NCT04325828 ↗ “goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months” NCT00776594 ↗ “Available drugs include triptorelin, goserelin, leuprolide, digareke ect.” NCT05406999 ↗ “* Goserelin (10.8 mg s.c. after randomisation and after three months) or” NCT01638247 ↗ “Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.” NCT06656624 ↗ “leuprolide and goserelin are gonadotropin-releasing hormone analogues” NCT00586898 ↗ “This includes leuprolide, goserelin, triptorelin, and degarelix.” NCT02972060 ↗ “10.8 mg depot for injection (equivalent to 10.8 mg goserelin)” NCT03658213 ↗ “Either goserelin acetate or leuprorelin Acetate is allowed.” NCT05333328 ↗ “switch to adjuvant anastrozole plus goserelin (ADD group)” PMID 30643455 ↗ Dec 2018 “* Goserelin: subcutaneous implant, 3.6 mg or 10.8 mg, or” NCT07553988 ↗ “Postmenopausal participants should use Goserelin.” NCT06447623 ↗ “Postmenopausal participants should use Goserelin.” NCT05949541 ↗ “Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m” NCT02221999 ↗ “leuprolide, goserelin, buserelin, or triptorelin” NCT01492972 ↗ “Goserelin, 3.6mg, subcutaneous injection, q28d” NCT04220398 ↗ “leuprolide, goserelin, triptorelin acetate” NCT04181203 ↗ “Goserelin: AstraZeneca, 10.8mg injection” NCT06772441 ↗ “Premenopause：Goserelin 3.6mg IM IM Q4W.” NCT04215003 ↗ “1. Goserelin(GnRHa) 3.6mg” NCT01622361 ↗ “Goserelin 10.8 mg” NCT00223145 ↗ “Drug: Goserelin” NCT00309478 ↗ “Goserelin” NCT05498272 ↗ “Goserelin” NCT04293393 ↗ “Goserelin” NCT05700903 ↗ “Goserelin” NCT07596212 ↗ |
| Known as | GNRH-A Goserelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05617885 ↗ |
| Known as | goserelin acetate | “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗80“Patients receive multitargeted tyrosine kinase inhibitor PLX3397 orally (PO) twice daily (BID) for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday)...” NCT02472275 ↗ “Primary Objective: * To determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing neoadjuvant and/or adjuvant...” NCT00429403 ↗ “All subjects will receive androgen deprivation therapy with a LHRH agonist (any LHRH agonist such as leuprolide acetate or goserelin acetate is acceptable) or a LHRH antagonist...” NCT02582749 ↗ “A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and...” NCT00099086 ↗ “The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according...” NCT03332797 ↗ “Goserelin acetate implant (ZOLADEX), at a dose of 10.8 mg, will be administered subcutaneously every 12 weeks into the anterior abdominal wall below the navel line.” NCT07450599 ↗ “Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to allogeneic haematopoietic stem cell transplantation conditioning.” NCT07552506 ↗ “either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.” NCT00016913 ↗ “luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.” NCT02217566 ↗ “3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation.” NCT00948805 ↗ “Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate).” NCT00430183 ↗ “LHRH agonists may include, but are not limited to, leuprolide acetate, goserelin acetate, or triptorelin pamoate.” NCT04961996 ↗ “for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses” NCT01717053 ↗ “GnRH analog Goserelin acetate 3.6 mg every 4 weeks with tamoxifen 20 mg daily for premenopausal patients” NCT05755581 ↗ “Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH).” NCT06455969 ↗ “goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months” NCT00776594 ↗ “Goserelin acetate (Zoladex) subcutaneously every 4 weeks” NCT04126070 ↗ “Goserelin Acetate 10.8 MG Subcutaneous Implant” NCT03899077 ↗ “Leuprorelin acetate, goserelin acetate” NCT05891093 ↗ “Goserelin Acetate 3.6 mg inj, implant” NCT06523530 ↗ “Goserelin acetate (Zoladex)” NCT00605267 ↗ “Drug: goserelin acetate” NCT00541047 ↗ “Drug: Goserelin Acetate” NCT00439751 ↗ “Drug: Goserelin Acetate” NCT03070886 ↗ “Drug: goserelin acetate” NCT00026377 ↗ “goserelin acetate” NCT03809000 ↗ |
| Known as | goserelin acetate (Zoladex) | “goserelin acetate (Zoladex®)” NCT01531205 ↗ |
| Known as | Goserelin Depot | “Drug: Goserelin Depot” NCT07552506 ↗ |
| Known as | NSC-606864 | “Flutamide, FLUT, NSC-147834; Goserelin, Zoladex, ZDX, NSC-606864; with irradiation of the whole pelvis followed by a boost to the prostate using photons of at least 6 MV.” NCT00769548 ↗ |
| Known as | ZDX | “Flutamide, FLUT, NSC-147834; Goserelin, Zoladex, ZDX, NSC-606864; with irradiation of the whole pelvis followed by a boost to the prostate using photons of at least 6 MV.” NCT00769548 ↗1“luteinizing hormone-releasing hormone (LHRH) analog (buserelin [BSRL], goserelin [ZDX], or leuprolide [LEUP])” NCT00003653 ↗ |
| Known as | Zoladex | “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗51“Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single...” NCT03054168 ↗ “Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout...” NCT06922318 ↗ “Patients in the combined-treatment group received 3.6 mg of goserelin (Zoladex) subcutaneously every four weeks starting on the first day of irradiation and continuing for three years” PMID 9233866 ↗ Jul 1997 “Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally” NCT01790126 ↗ “Flutamide, FLUT, NSC-147834; Goserelin, Zoladex, ZDX, NSC-606864; with irradiation of the whole pelvis followed by a boost to the prostate using photons of at least 6 MV.” NCT00769548 ↗ “CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection” NCT02932761 ↗ “Goserelin acetate implant (ZOLADEX), at a dose of 10.8 mg, will be administered subcutaneously every 12 weeks into the anterior abdominal wall below the navel line.” NCT07450599 ↗ “luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix)” NCT06059118 ↗ “monthly injections of a luteinizing hormone-releasing hormone (LHRH) analog such as Lupron or Zoladex” NCT00283803 ↗ “group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)” NCT01218581 ↗ “Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy” NCT01530607 ↗ “Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2” NCT00006359 ↗ “Zoladex is administered subcutaneously and Lupron is administered intramuscularly.” NCT00658697 ↗ “Groups 1-5 will receive goserelin acetate (Zoladex) plus 0 (placebo gel)” NCT00114114 ↗ “LHRH agonist or antagonist (e.g. Eligard, Zoladex, Lupron, Orgovyx)” NCT07142551 ↗ “bicalutamide (Casodex), goserelin (Zoladex)” NCT00293696 ↗ “AA: Lupron 22.5 mg or Zoladex 10.8 mg” NCT00970203 ↗ “2. Zoladex/ Flutamide” NCT02911350 ↗ “Goserelin (Zoladex)” NCT00293670 ↗ “Zoladex®” NCT03809000 ↗ “Zoladex” NCT00005044 ↗ “Zoladex” NCT00165399 ↗ |
| Known as | Zoladex LA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01673984 ↗ |
| Known as | ZOLADEXTM | “patients added Goserelin(ZOLADEXTM) to Tamoxifen” NCT00912548 ↗ |
| Action | Inhibit | “Leuprolide and goserelin-both approved to treat prostate cancer-reduce testosterone production” NCT00004635 ↗ |
| Modality | Other / unclassified | “Zoladex, a kind of luitinizing hormone releasing hormone analogue, can offer efficient estrogen suppression as well.” NCT00488722 ↗ |
| Route | Subcutaneous | “goserelin subcutaneously (SC)” NCT00002580 ↗ |